These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 20940450

  • 1. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.
    Sarullo FM, Fazio G, Puccio D, Fasullo S, Paterna S, Novo S, Di Pasquale P.
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):349-55. PubMed ID: 20940450
    [Abstract] [Full Text] [Related]

  • 2. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009 Dec; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 3. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.
    Russell SD, Selaru P, Pyne DA, Ghazzi MM, Massey KD, Pressler M, Serikoff A, Coats AJ.
    Am Heart J; 2003 Jan; 145(1):179-86. PubMed ID: 12514672
    [Abstract] [Full Text] [Related]

  • 4. Short-term improvement in submaximal exercise capacity by optimized therapy with ACE inhibitors and beta blockers in heart failure patients is associated with restoration of peripheral endothelial function.
    Poelzl G, Frick M, Lackner B, Huegel H, Alber HF, Mair J, Herold M, Schwarzacher SP, Pachinger O, Weidinger F.
    Int J Cardiol; 2006 Mar 22; 108(1):48-54. PubMed ID: 16516697
    [Abstract] [Full Text] [Related]

  • 5. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
    Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H.
    Int J Cardiol; 2005 Aug 18; 103(2):182-6. PubMed ID: 16080978
    [Abstract] [Full Text] [Related]

  • 6. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan 18; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 7. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM, Vitale C, Volterrani M.
    Adv Ther; 2010 Apr 18; 27(4):202-10. PubMed ID: 20495895
    [Abstract] [Full Text] [Related]

  • 8. Chronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: time to pace?
    Jorde UP, Vittorio TJ, Kasper ME, Arezzi E, Colombo PC, Goldsmith RL, Ahuja K, Tseng CH, Haas F, Hirsh DS.
    Eur J Heart Fail; 2008 Jan 18; 10(1):96-101. PubMed ID: 18096432
    [Abstract] [Full Text] [Related]

  • 9. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Jan 18; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 10. Effects of neurohormonal antagonism on symptoms and quality-of-life in heart failure.
    Metra M, Nodari S, D'Aloia A, Madureri A, Rosselli F, Bontempi L, Zanini R, Dei Cas L.
    Eur Heart J; 1998 Feb 18; 19 Suppl B():B25-35. PubMed ID: 9519349
    [Abstract] [Full Text] [Related]

  • 11. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar 18; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 12. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010 Mar 18; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.